List of Excipients in Branded Drug REVATIO
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| PFIZER LABORATORIES DIV PFIZER INC | REVATIO | sildenafil citrate | 0069-4190 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | |
| PFIZER LABORATORIES DIV PFIZER INC | REVATIO | sildenafil citrate | 0069-4190 | CELLULOSE, MICROCRYSTALLINE | |
| PFIZER LABORATORIES DIV PFIZER INC | REVATIO | sildenafil citrate | 0069-4190 | CROSCARMELLOSE SODIUM | |
| PFIZER LABORATORIES DIV PFIZER INC | REVATIO | sildenafil citrate | 0069-4190 | HYPROMELLOSE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Revatio Excipient Strategy and Commercial Opportunities in Pulmonary Arterial Hypertension
Revatio is Pfizer’s sildenafil citrate product for pulmonary arterial hypertension (PAH). Its commercial protection is now driven primarily by clinical positioning, formulation performance, supply reliability, and channel access rather than core compound patents. The strongest excipient opportunities are pediatric and dysphagia-friendly liquid formulations, ready-to-use hospital presentations, taste-masked dosage forms, and stable low-dose products for weight-based dosing.
What is Revatio and which formulations are commercially relevant?
Revatio contains sildenafil citrate, a phosphodiesterase-5 inhibitor that increases cyclic guanosine monophosphate signaling and reduces pulmonary vascular resistance. The FDA approved Revatio tablets in 2005 for adults with PAH, followed by an intravenous formulation and an oral suspension presentation.[1]
| Product | Strength or presentation | Route | Primary commercial use |
|---|---|---|---|
| Revatio tablets | 20 mg sildenafil equivalent | Oral | Chronic adult PAH therapy |
| Revatio oral suspension | 10 mg/mL | Oral | Pediatric and adult patients unable to swallow tablets |
| Revatio injection | 10 mg/12.5 mL, equivalent to 0.8 mg/mL | Intravenous | Hospital transition or temporary oral-therapy replacement |
The 20 mg tablet is a conventional immediate-release solid dosage form. The oral suspension is the most important formulation platform for excipient-based differentiation because it must address taste, sedimentation, dose uniformity, microbial control, reconstitution, storage, and administration accuracy.
What excipients are used in Revatio formulations?
The Revatio tablet uses standard immediate-release excipients. The oral suspension uses a vehicle and stabilizer system designed for an aqueous, multidose product.
Revatio tablet excipients
The Revatio tablet label identifies excipients including:
- Microcrystalline cellulose
- Anhydrous dibasic calcium phosphate
- Croscarmellose sodium
- Hypromellose
- Magnesium stearate
- Titanium dioxide
- Triacetin
These materials support tablet compression, disintegration, coating, lubrication, opacity, and physical stability.[1]
The tablet system is technically conventional. It offers limited room for meaningful product differentiation unless a developer changes the dose size, tablet geometry, swallowability, disintegration profile, or packaging configuration.
Revatio oral suspension excipients
The oral suspension uses a liquid vehicle containing excipients such as:
- Sorbitol
- Citric acid
- Sodium citrate
- Xanthan gum
- Titanium dioxide
- Colloidal silicon dioxide
- Sucralose
The formulation is designed to maintain sildenafil in a dispersed and administrable form while improving palatability. Sorbitol provides bulk and sweetness. Xanthan gum increases viscosity and helps suspend particles. Citric acid and sodium citrate provide pH control. Sucralose contributes sweetness without adding substantial volume.[1]
This excipient architecture creates commercial tradeoffs. Higher viscosity can improve dose uniformity but make withdrawal through an oral syringe more difficult. Sorbitol can cause gastrointestinal discomfort in sensitive patients. Sweeteners and flavor systems can improve adherence but may create compatibility, stability, or regional labeling issues.
What excipient strategy is most attractive for Revatio?
The most attractive strategy is a patient-centered liquid platform that improves administration without changing sildenafil exposure materially.
Taste masking
Sildenafil can produce a bitter or unpleasant taste. Sucralose alone may not fully mask the active ingredient, particularly at higher liquid doses. Commercial developers can evaluate:
- Ion-exchange resins
- Polymer-coated drug particles
- Lipid-based taste-masking systems
- Cyclodextrin complexes
- Multiparticulate suspensions
- Flavored, buffered aqueous vehicles
Taste masking is especially relevant for pediatric PAH patients, who may receive repeated doses over long treatment periods. A formulation that reduces bitterness can improve adherence and reduce caregiver resistance.
The main technical constraint is dose uniformity. Coating or complexation cannot materially delay dissolution or reduce bioavailability. Taste-masking systems therefore require comparative dissolution, particle-size, redispersibility, and pharmacokinetic testing.
Low-viscosity suspensions
A liquid product must remain physically stable while allowing accurate withdrawal with a dosing syringe. Xanthan gum is effective at low concentrations, but excessive viscosity can slow syringe filling and create residual volume in the bottle.
A lower-viscosity alternative using a different suspending polymer or a structured vehicle may provide a commercial advantage if it delivers:
- Rapid redispersion after mild shaking
- Low sedimentation
- Accurate 1 mL or sub-mL dosing
- Reduced bottle and syringe residue
- Stable performance after repeated opening
This is a practical opportunity because PAH dosing may be weight-based and patients may require small volumes.
Ready-to-use liquid dosage forms
The marketed suspension requires reconstitution before use. A ready-to-use formulation could remove several handling steps:
- No reconstitution error
- No requirement for purified or potable water during preparation
- Lower caregiver burden
- More consistent final concentration
- Easier dispensing from specialty pharmacies
The main development barriers are chemical stability in water, microbial preservation, container-closure compatibility, and shelf life. A developer may need to select a preservative system, oxygen-control strategy, or single-dose packaging.
Preservative-free unit doses
Preservative-free unit-dose cups or prefilled oral syringes could target hospitals, pediatric centers, and specialty pharmacies. This approach would increase packaging cost but reduce multidose contamination risk and dosing errors.
Unit-dose presentations also could support inpatient medication administration where pharmacy-controlled dosing is preferred. The opportunity is stronger for pediatric and institutional channels than for routine adult outpatient use.
What formulation patents protect Revatio and how strong is the patent estate?
The foundational sildenafil compound and early use patents have expired in the United States. The core sildenafil patent, U.S. Patent No. 5,250,534, expired in 2012, subject to applicable patent-term adjustments and extensions.[2]
Revatio’s commercial protection is therefore materially weaker than that of a newly launched branded PAH therapy. The principal barriers are regulatory, clinical, manufacturing, and market-access barriers rather than basic compound exclusivity.
| Protection category | Revatio position | Commercial effect |
|---|---|---|
| Sildenafil compound patent | Expired | Generic manufacture permitted |
| Adult PAH use protection | Expired or no longer a meaningful barrier | Limited ability to block generic tablets |
| Tablet formulation | Conventional formulation | Low differentiation value |
| Oral suspension | Formulation and handling know-how remain relevant | Potential for product-level differentiation |
| Intravenous product | Sterility and manufacturing complexity | Higher operational barrier than tablets |
| Regulatory exclusivity | Historical exclusivity has ended | Generic entry enabled |
| Trade secrets | Possible manufacturing and stability know-how | Difficult to enforce against independent development |
A new excipient formulation could receive patent protection if it claims a novel composition, particle architecture, stability profile, dosing system, or manufacturing process. Generic use of the same excipients in a conventional formulation would not normally infringe a narrowly drafted formulation claim.
What is the Orange Book status of Revatio?
Revatio was approved under NDA 021845. The FDA Orange Book identifies approved drug products and listed patent information, but the presence or absence of a listed patent does not itself determine all potential patent exposure.[3]
The practical position is that Revatio’s original exclusivity has ended and sildenafil products are available from multiple generic manufacturers. A sponsor evaluating a new Revatio formulation should not rely on the historic brand name for market exclusivity. Protection would need to come from:
- A differentiated dosage form
- A new formulation claim
- A pediatric or administration advantage
- A device or container-closure combination
- A new clinical use supported by regulatory approval
- Contracting and specialty-channel execution
A 505(b)(2) pathway may be relevant for a materially different sildenafil formulation, particularly if the product changes the dosage form, route, strength, excipient system, or administration method. A standard equivalent tablet would generally face a more direct generic pathway.
When did Revatio lose exclusivity and when can generic products launch?
Revatio’s early U.S. exclusivity periods have ended. Generic sildenafil tablets entered the market after expiration of the relevant compound and use protections. Generic competition has compressed the price of standard 20 mg sildenafil tablets and reduced the ability of Pfizer to preserve premium pricing through the tablet alone.
Generic entry scenarios differ by product type:
| Product type | Generic entry risk | Reason |
|---|---|---|
| 20 mg tablet | High | Mature compound, conventional dosage form, multiple suppliers |
| Oral suspension | Moderate to high | Formulation and device requirements are more demanding |
| Intravenous sildenafil | Moderate | Sterile manufacturing and hospital procurement barriers |
| Taste-masked pediatric product | Lower initially | Potential formulation and clinical differentiation |
| Ready-to-use unit-dose liquid | Lower initially | Packaging, stability, and supply-chain complexity |
A generic tablet launch does not automatically replicate the commercial value of a well-designed liquid product. Pediatric hospitals, specialty pharmacies, and caregivers may prioritize administration reliability over the lowest tablet price.
What manufacturing and excipient barriers affect Revatio competition?
The main manufacturing barriers are not the availability of basic excipients. Microcrystalline cellulose, magnesium stearate, sorbitol, xanthan gum, citric acid, and sodium citrate are widely available. The barriers arise from process control and finished-product performance.
Critical manufacturing controls
A competitive suspension must control:
- Sildenafil particle size and agglomeration
- Wetting and dispersion
- Viscosity across the shelf life
- Sedimentation and redispersibility
- pH drift
- Preservative effectiveness
- Microbial limits
- Dose uniformity throughout bottle use
- Extractables and leachables
- Compatibility with oral syringes and dosing adapters
The active ingredient is practically insoluble in water, which makes particle engineering and suspension control important. A formulation that appears acceptable immediately after manufacture may fail after temperature cycling, prolonged storage, or repeated opening.
Supply-chain opportunities
Excipient suppliers can pursue value through:
- Pharmaceutical-grade xanthan gum with tighter viscosity specifications
- Co-processed suspending systems
- Direct-compression excipient blends for sildenafil tablets
- Low-peroxide and low-moisture excipient grades
- Ready-to-use oral suspension vehicles
- Single-dose liquid packaging
- Oral syringe and bottle-adapter systems
The commercial proposition should focus on reduced development time, predictable batch performance, and regulatory support rather than commodity pricing.
Which companies are challenging Revatio commercially?
Pfizer faces competition from generic sildenafil manufacturers, including large multinational generic companies and regional suppliers. The competitive field includes manufacturers that market sildenafil tablets and, depending on jurisdiction, oral liquid or compounded products.
The principal competitive categories are:
- Generic 20 mg sildenafil tablets.
- Hospital-prepared or pharmacy-compounded oral liquids.
- Alternative PDE-5 inhibitors, particularly tadalafil.
- Other PAH therapies, including endothelin-receptor antagonists, prostacyclin-pathway agents, and soluble guanylate cyclase stimulators.
- Combination regimens that reduce reliance on sildenafil monotherapy.
Compounded liquids can compete with branded suspension products when pharmacies have the necessary formulation capability. They may have inconsistent taste, stability, concentration, or microbial controls, creating an opening for a regulated commercial liquid with validated shelf life and dosing accuracy.
How does Revatio compare with tadalafil-based PAH products?
Revatio and tadalafil-based PAH products compete within the PDE-5 inhibitor segment but differ in dosing and formulation economics.
| Attribute | Revatio | Tadalafil PAH product |
|---|---|---|
| Active ingredient | Sildenafil | Tadalafil |
| Typical adult dosing pattern | More frequent dosing | Once daily |
| Liquid opportunity | Established suspension platform | Depends on product and jurisdiction |
| Generic pressure | High | High, but timing varies by market |
| Pediatric formulation need | Significant | Also relevant |
| Adherence advantage | Liquid and hospital options | Lower dosing frequency |
Sildenafil has a stronger established liquid and intravenous use case. Tadalafil has a potential adherence advantage from less frequent dosing. An excipient strategy for Revatio must therefore compete on administration, dose flexibility, onset expectations, pediatric use, and institutional workflow.
What licensing and partnering opportunities exist?
The most credible licensing opportunities involve formulation technology rather than the sildenafil molecule.
Potential transaction structures include:
- Licensing a taste-masking platform for pediatric sildenafil
- Supplying a ready-to-use suspension vehicle
- Co-developing unit-dose oral syringes
- Contract manufacturing of sterile intravenous sildenafil
- Regional commercialization of a differentiated liquid product
- Supplying specialty pharmacies with validated compounded or commercial formulations
No major public licensing transaction is required to commercialize a generic sildenafil tablet. Licensing becomes more valuable when the partner contributes proprietary excipient technology, regulatory documentation, pediatric data, sterile capacity, or specialty distribution.
What revenue exposure does Revatio have?
Pfizer does not generally report Revatio revenue as a separately material line item in public financial reporting. Generic erosion and competition from other PAH therapies have reduced the strategic value of the standard tablet franchise.
Revenue opportunities remain in narrower segments:
- Pediatric PAH
- Patients unable to swallow tablets
- Hospital intravenous therapy
- Specialty-pharmacy distribution
- Countries with limited generic competition
- Unit-dose and ready-to-use liquid products
- Contract manufacturing and excipient supply
A differentiated liquid product can command a higher price than a conventional tablet if it demonstrates measurable benefits in adherence, dose accuracy, caregiver handling, or hospital workflow. The premium must offset the cost of stability studies, packaging, pediatric development, and specialty distribution.
What generic launch risks exist for a new Revatio formulation?
A new product faces five principal risks:
- A low-cost generic tablet may substitute for the branded product where patients can swallow tablets.
- Compounding pharmacies may offer lower-cost liquids.
- FDA may require additional clinical or bridging data for a materially different formulation.
- Formulation patents may be difficult to enforce if claims are narrow.
- Large generic manufacturers may reproduce the commercial concept after design-around.
The best defense is a product with multiple forms of differentiation: proprietary taste masking, a validated device, a clinically useful concentration, strong pediatric usability data, and reliable specialty distribution.
Key Takeaways
- Revatio is sildenafil citrate for PAH, marketed in tablet, oral suspension, and intravenous forms.
- The core sildenafil patent estate has expired, and standard tablet competition is intense.
- The oral suspension is the strongest platform for excipient-led differentiation.
- Taste masking, low viscosity, redispersibility, preservative control, and dose accuracy are the highest-value technical targets.
- Ready-to-use liquids, preservative-free unit doses, and prefilled oral syringes offer commercial opportunities.
- Generic tablet entry risk is high; liquid and intravenous competition is constrained by formulation and manufacturing requirements.
- A new product would need formulation, device, clinical, or channel differentiation to support premium pricing.
- Licensing value is concentrated in excipient systems, pediatric delivery, specialty manufacturing, and regulated liquid products.
FAQs About Revatio Excipients and Commercial Strategy
Can a new excipient formulation of sildenafil receive patent protection?
Yes. A formulation may be patentable if it has a novel composition, particle system, stability profile, dosage form, device combination, or manufacturing process. Standard use of known excipients in a conventional tablet is unlikely to provide strong protection.
Is Revatio oral suspension better than a compounded sildenafil liquid?
A regulated commercial suspension can offer validated concentration, stability, microbial controls, labeling, and dosing instructions. A compounded product may be less expensive but can vary in taste, shelf life, and performance.
What is the best pediatric excipient opportunity for sildenafil?
A palatable, ready-to-use, low-viscosity suspension with accurate oral-syringe dosing is the strongest opportunity. Taste masking must not compromise dissolution or bioavailability.
Can a 505(b)(2) application support a new Revatio liquid?
Potentially. A materially different sildenafil dosage form, concentration, excipient system, or administration method may support a 505(b)(2) strategy, subject to FDA requirements for bridging and product-specific data.
Does intravenous Revatio remain commercially attractive?
It can remain attractive in hospitals where patients temporarily cannot take oral therapy. Sterile manufacturing, hospital procurement, and limited-volume demand make the opportunity narrower than the oral market.
References
- U.S. Food and Drug Administration. (2024). Revatio (sildenafil citrate) prescribing information.
- U.S. Patent and Trademark Office. (1993). U.S. Patent No. 5,250,534: Pyrazolo[4,3-d]pyrimidin-7-one antianginal agents.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
Deeper Knowledge, Faster
- Identify first generic entrants
- Obtain formulation and manufacturing information
- Drug patents in 130+ countries